EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Consensus Predictions Have Deteriorated Slightly Following Its Recent Report
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 09 2025
0mins
Source: Yahoo Finance
Disappointing Earnings Report: EyePoint Pharmaceuticals reported third-quarter revenues of $966k, falling 71% short of analyst expectations, with losses per share at $0.85, exceeding forecasts by 11%.
Analyst Forecast Adjustments: Following the earnings report, analysts revised their revenue expectations for 2026 down to $7.23m, indicating an 83% decline from the previous year, while losses per share are expected to increase to $2.79.
Price Target Stability: Despite the negative revisions in revenue and earnings forecasts, the average price target for EyePoint Pharmaceuticals remains unchanged at $34.58, reflecting a lack of long-term impact from the recent earnings results.
Industry Comparison: EyePoint's projected revenue decline contrasts sharply with the broader industry, which is expected to grow at an annual rate of 9.1%, highlighting significant underperformance relative to peers.
Get Free Real-Time Notifications for Any Stock
Monitor tickers like EYPT with instant alerts to capture every critical market movement.
Sign up for free to build your custom watchlist and receive professional-grade stock notifications.
Analyst Views on EYPT
Wall Street analysts forecast EYPT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for EYPT is 31.50 USD with a low forecast of 20.00 USD and a high forecast of 43.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Analyst Rating
6 Buy
0 Hold
0 Sell
Strong Buy
Current: 15.040
Low
20.00
Averages
31.50
High
43.00
Current: 15.040
Low
20.00
Averages
31.50
High
43.00
About EYPT
EyePoint, Inc., formerly EyePoint Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The Company’s lead product candidate, DURAVYU, is an investigational-sustained delivery treatment for serious retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor, with bioerodible Durasert E technology. Vorolanib features a novel multi-mechanism of action as it targets both vascular endothelial growth factor (VEGF)-mediated vascular permeability and IL-6 mediated inflammation through inhibition of all VEGF receptors and pro-inflammatory IL-6/JAK1 signaling. DURAVYU is in Phase III pivotal trials for wet age-related macular degeneration. DURAVYU is also being advanced for the treatment of diabetic macular edema (DME) with the first patient dosing in Phase III trials.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Biotech Stocks Surge at Year-End 2025, ETFs Gain 35.84%
- Sector Recovery: The iShares Biotechnology ETF surged 29.51% year-to-date by December 2025, while the State Street SPDR S&P Biotech ETF achieved an even higher gain of 35.84%, indicating a significant recovery in investor confidence in the biotech sector.
- Surge in M&A Activity: Six of the year's ten largest biopharma deals occurred in Q4, with Johnson & Johnson spending $14.6 billion on Intra Cellular Therapies, signaling a strong commitment from big pharma to expand their pipelines through acquisitions.
- FDA Approvals Boost Innovation: The FDA approved 44 new therapies in 2025, with 26 approvals in the second half, including Cytokinetics' Myqorzo after 27 years, highlighting a supportive regulatory environment for innovation.
- Clinical Trial Successes: Structure Therapeutics saw its stock more than double after its obesity drug trials showed over 15% weight loss in patients, demonstrating the direct impact of clinical success on company valuations.
Continue Reading
EyePoint CEO Jay Duker to Present at 2026 J.P. Morgan Healthcare Conference
- Key Conference Presentation: EyePoint, Inc. CEO Jay S. Duker will present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026, showcasing the company's innovative advancements in retinal disease treatments, which is expected to attract investor interest and enhance corporate visibility.
- Clinical Trial Progress: EyePoint's lead product DURAVYU™ is currently undergoing Phase 3 pivotal trials, with topline data expected in mid-2026, which will provide crucial support for the company's future market launch and fundraising efforts.
- Product Innovation: DURAVYU™ combines the selective tyrosine kinase inhibitor vorolanib with next-generation bioerodible Durasert E™ technology, aimed at improving the quality of life for patients with serious retinal diseases, demonstrating the company's technological edge in the biopharmaceutical sector.
- Market Potential: EyePoint is committed to partnering with the retina community to drive long-term value creation, having approved four drugs over three decades and treated tens of thousands of eyes, indicating a strong foundation and future growth potential in the retinal disease treatment market.
Continue Reading